Status:
UNKNOWN
Hydroxychloroquine, Azithromycin in the Treatment of Covid-19
Lead Sponsor:
Centre Hôpital Universitaire Farhat Hached
Conditions:
SARS-CoV-2 Pneumonia
COVID-19
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study investigates the efficay and tolerance of 5-days course of hydroxychloroquine or hydroxychloroquine and azithromycin of patients with COVID-19 infection. The investigators will undertake a ...
Detailed Description
There is a critical need to identify effective treatments and a number of molecules have been suggested, but The investigators still do not have enough evidence about their efficacy, to treat COVID-19...
Eligibility Criteria
Inclusion
- PositiveSARS-COV-2 RT-PCR in hospitalized patients in University Hospital Farhat Hached in Sousse Tunisia.
- Had either not received hydroxychloroquine before or had received hydroxychloroquine for at least 1 day and could tolerate a dose of 200 mg of hydroxychloroquine/day.
Exclusion
- Unableto take oral medication, pregnancy or breast feeding, immune-compromised patients,
- Contraindicationto the studied medications
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04405921
Start Date
July 1 2020
End Date
March 1 2021
Last Update
June 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Farhat Hached
Sousse, Tunisia, 4000